4.5 Article

Rifaximin use favoured micafungin-resistant Candida spp. infections in recipients of allogeneic hematopoietic cell transplantation

期刊

ANNALS OF HEMATOLOGY
卷 100, 期 9, 页码 2375-2380

出版社

SPRINGER
DOI: 10.1007/s00277-021-04569-x

关键词

Candida; Rifaximin; Hematopoietic stem cell transplantation; Microbiome; Prophylaxis; Echinocandin

资金

  1. Universita degli Studi di Perugia within the CRUI-CARE Agreement
  2. Associazione Italiana per la Ricerca sul Cancro (AIRC) [20456]

向作者/读者索取更多资源

The study evaluated the safety and outcomes of using rifaximin prophylaxis in patients undergoing hematopoietic stem cell transplantation, finding an increased risk of Candida spp. infections in rifaximin-treated patients compared to historical controls, highlighting the need for larger prospective studies to assess the overall impact of rifaximin prophylaxis on patient outcomes.
Damage to gut mucosa following conditioning regimens may favour bacterial infections that can trigger graft versus host disease (GvHD) in patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT). Rifaximin, an oral and non-absorbable antibiotic, has been recently proposed as effective prophylaxis to reduce bacterial infections in the gut and consequently acute GvHD in this setting. The present study evaluated safety and outcomes of HSCT patients that were treated with rifaximin prophylaxis at Perugia University Hospital. Rifaximin prophylaxis was introduced as standard of care in HSCT patients in May 2018. We retrieved data from 118 consecutive transplants, and we compared the outcomes of rifaximin-treated patients with historical controls that did not receive antibiotic prophylaxis. While incidences of neutropenic fever, documented bacterial infections, and aGvHD were similar in the two groups, we found an increased frequency of invasive candidiasis and clinically relevant Candida spp. infections in rifaximin-treated patients (5 patients vs 1 patient, 25% [+/- 0.99%] vs 1% [+/- 0.01%], p < .0001). Three rifaximin-treated patients experienced life-threating candidemia (2 C. krusei, 1 C. orthopsilosis). Rifaximin was the only factor that increased the risk of Candida spp. infections. Rifaximin could have contributed to microbiome disruption which favoured an outbreak of life-threatening Candida infections. This important complication forced us to halt its use. Larger, prospective studies are needed to assess the impact of rifaximin prophylaxis on incidence of bacterial infections, aGvHD, and survival of HSCT patients.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据